imugene-gets-chinese-patent-application-for-drug-delivery-technology-linguet

Aus drug delivery technology gets Chinese patent

  • China
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Australian drug delivery technology company Imugene has received key Chinese patent application for the company's novel drug delivery technology Linguet.... Read more

over-expression-of-cd33-in-support-cells-prevents-them-from-clearing-out-toxic-plaques-thus-promoting-late-onset-of-alzheimer-s-disease

Excess CD33 promotes late onset of Alzheimer's

  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Scientists funded by the National Institutes of Health (NIH) have discovered a potential strategy for developing treatments to stem the progression process... Read more

fosun-pharma-and-pramerica-fosun-fund-spend-usd240-million-to-acquire-95

Fosun Pharma buys laser medtech firm for $240 mn

  • China
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

‎Singapore: Shanghai-based Fosun Pharmaceutical, along with Pramerica-Fosun Fund, is acquiring a 95.6 percent stake in Israel-based Alma Lasers for $240 million. The... Read more

shanghai-pharma-revenue-rises-17

Shanghai Pharma revenue rises 17.6% to $3.17 bn

  • China
  • |
  • Company Results
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

‎Singapore: Shanghai Pharmaceuticals has maintained a steady growth in first quarterly result of 2013 touching operating revenues of $3.17 billion (RMB19.59 billion),... Read more

qiagen-is-going-to-make-changes-in-the-membership-of-the-supervisory-board

Qiagen makes changes in supervisory board

  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Qiagen is going to make changes in the membership of the supervisory board that will be put forward for approval by shareholders at the next annual general... Read more

takeda-disagrees-with-jury-s-decision-to-give-jack-cooper-and-other-plaintiffs-usd6

Takeda asks judge to rule in its favor

  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Takeda Pharmaceuticals, US, highlighted that in the case against Jack Cooper (No CGC-12-518535) the jury ruled in favor of the plaintiffs and awarded... Read more

mutation-in-ercc4-not-only-causes-xeroderma-pigmentosum-and-progeria-but-also-fanconi-anemia

Study discovers single gene that controls 3 diseases

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: An international research consortium led by the Universitat Autònoma de Barcelona (UAB), Spain; Ciberer and the University of Wurzburg, Germany, discovered... Read more

ema-grants-marketing-nod-to-nuedexta-a-drug-used-to-treat-pseudobulbar-in-which-patients-experience-uncontrollable-bouts-of-laughing-or-crying-image-source-www

EMA nod for 'uncontrollable laughter' disease drug

  • Europe
  • |
  • Regulatory
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a marketing authorization for Nuedexta,... Read more

bruker-daltonics-to-distribute-technical-support-for-bd-bruker-maldi-biotyper-system-automated-antimicrobial-susceptibility-testing

Bruker to distribute BD's MS technology

  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: BD Diagnostics has collaborated with Bruker Daltonics to sell and distribute front-line technical support for the co-labeled BD Bruker Maldi Biotyper... Read more

global-polio-eradication-initiative-gpei-presents-polio-eradication-and-endgame-strategic-plan-2013-18-at-global-vaccine-summit

Philanthropists pledge $4bn for polio eradication

  • Rest of Asia
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: The Global Polio Eradication Initiative (GPEI) presented a first-of-its-kind comprehensive six-year plan, titled 'Polio Eradication and Endgame Strategic... Read more

ema-nod-for-genzyme-s-matrix-induced-autologous-chondrocyte-implantation-maci-for-repair-of-symptomatic-full-thickness-knee-cartilage-defects

EMA nod for knee cartilage repair product

  • Europe
  • |
  • Regulatory
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Genzyme's matrix-induced... Read more

european-medicine-agency-s-ema-committee-for-medicinal-products-for-human-use-chmp-recommends-that-protelososseor-should-only-be-used-to-treat-severe-osteoporosis-in-postmenopausal-women-and-severe-osteopor

EMA: Osteoporosis drug causes heart problems

  • Europe
  • |
  • Regulatory
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: The European Medicine Agency (EMA) recommended restriction in the use of the osteoporosis medicine Protelos/Osseor, following an assessment of data showing... Read more

happy-news-for-novartis-geneva-production-site-employees-novartis-will-invest-usd160-million-until-2020

Novartis spends $160 mn to jumpstart factory

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Novartis is going to invest $160 million (CHF150 million) until 2020 to bolster its production site near Geneva. The firm was contemplating a shut down... Read more

quintiles-ipo-offers-19

Quintiles files 19mn shares IPO to raise $790 mn

  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Quintiles Transnational Holdings, which is the biggest provider of testing services to drugmakers, has filed for an initial public offering (IPO), seeking... Read more

novartis-getting-sued-is-becoming-a-habit

US govt sues Novartis for second time in a week

  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: The US government has filed another case against Novartis Pharmaceuticals, this time in the US District Court in Manhattan, alleging that the pharma giant... Read more

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X